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Article focus
  bAcH is a new classification system for 
long bone osteomyelitis. this study 
serves to validate this classification in 
terms of interuser assessment and opti-
mize specific variables that are included 
in the classification.
Key messages
  bAcH can be applied with good accuracy 
and reproducibility to varied cases of 
long bone osteomyelitis.
  to classify the bone involvement of 
osteomyelitis, a clinical imaging utility 
should be used that allows 3D visualiza-
tion of the pattern of infection.
  the absolute number of resistant suscep-
tibility tests performed for a bacterial iso-
late has a high correlation with multidrug 
resistance as defined by the european 
Society of clinical Microbiology and 
Infectious Diseases (eScMID).
Strengths and limitations
  this study assesses the reproducibility of 
the bAcH classification system with users 
who have a variety of clinical backgrounds 
and experience in the management of 
osteomyelitis.
The BAcH classification of long  
bone osteomyelitis
Objectives
The aim of this study was to assess the clinical application of, and optimize the variables 
used in, the BAcH classification of long-bone osteomyelitis.
Methods
A total of 30 clinicians from a variety of specialities classified 20 anonymized cases of long-
bone osteomyelitis using BAcH. cases were derived from patients who presented to spe-
cialist centres in the United Kingdom between october 2016 and April 2017. Accuracy and 
Fleiss’ kappa (Fκ) were calculated for each variable. Bone involvement (B-variable) was 
assessed further by nine clinicians who classified ten additional cases of long bone osteo-
myelitis using a 3D clinical imaging package. Thresholds for defining multidrug-resistant 
(MDR) isolates were optimized using results from a further analysis of 253 long bone osteo-
myelitis cases.
Results
The B-variable had a classification accuracy of 77.0%, which improved to 95.7% when 
using a 3D clinical imaging package (p < 0.01). The A-variable demonstrated difficulty in 
the accuracy of classification for increasingly resistant isolates (A1 (non-resistant), 94.4%; 
A2 (MDR), 46.7%; A3 (extensively or pan-drug-resistant), 10.0%). Further analysis demon-
strated that isolates with four or more resistant test results or less than 80% sensitive sus-
ceptibility test results had a 98.1% (95% confidence interval (cI) 96.6 to 99.6) and 98.8% 
(95% cI 98.1 to 100.0) correlation with MDR status, respectively. The coverage of the soft 
tissues (c-variable) and the host status (H-variable) both had a substantial agreement 
between users and a classification accuracy of 92.5% and 91.2%, respectively.
Conclusions
The BAcH classification system can be applied accurately by users with a variety of clinical 
backgrounds. Accuracy of B-classification was improved using 3D imaging. The use of the 
A-variable has been optimized based on susceptibility testing results.
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  this study proposes a classification system that can be 
used in clinical practice and in subsequent prospec-
tive studies.
Introduction
osteomyelitis is a complex disease that carries a signifi-
cant burden for patients.1 Specialist knowledge and 
treatment are essential for the successful management of 
patients with bone and joint infections.2 A method of 
stratifying patients is necessary to ensure that referral to 
specialist teams occurs at an appropriate time during the 
management process. one tool to address this need is a 
clinically applicable method of classifying osteomyelitis.
With the aim of establishing a new classification sys-
tem, we previously performed a systematic review that 
revealed 13 classification systems for osteomyelitis.3 
After an in-depth analysis and using a multidisciplinary 
approach, we hypothesized that four key variables for 
classification would guide prognosis and requirement for 
referral to a specialist treatment centre. these were the 
following, from which the acronym bAcH arises: 1) the 
bone involvement (b-variable); 2) the antimicrobial 
options (A-variable); 3) the coverage of the soft tissue 
(c-variable); and 4) the host status (H-variable).3 the 
bone involvement was divided into three options based 
on the presence of cavitary involvement (which includes 
a cortical, medullary, and non-segmental corticomedul-
lary infection) (b1), segmental involvement (b2), or the 
concomitant involvement of a joint irrespective of the 
segmental or cavitary infection (b3). the antimicrobial 
options used the european Society of Microbiology and 
Infectious Diseases (eScMID) criteria for stratifying iso-
lates into multidrug-resistant (MDr), extensively drug-
resistant (XDr), and pan-drug-resistant (PDr) isolates,4 
and in case of a foreign body, whether an antimicrobial 
compound with activity against adhering (biofilm) bacte-
ria was available. the coverage of the soft tissues was 
classified based on whether patients required plastic sur-
gical expertise for skin closure after surgical excision of 
the infection. the host status stratified patients based on 
the presence or absence of comorbidities such as diabe-
tes mellitus, vascular or immune compromise, or the 
presence of recurrent osteomyelitis following previous 
reconstructive surgery. the host status also accounted 
for patients who did not require an operation, were not 
fit enough to receive an anaesthetic, or declined surgery.
based on the classification of these individual varia-
bles, the complexity of osteomyelitis can be determined. 
each variable in bAcH is stratified into either ‘uncompli-
cated’ or ‘complex’. In two variables, the antimicrobial 
options and the host status, osteomyelitis can also be 
stratified as having ‘few or no options available’. the 
overall complexity of the osteomyelitis is determined by 
classification of the most severely classified variable.
Several steps are mandatory to validate a classification 
system. First, we analyzed the applicability to a retrospec-
tive cohort. the promising results of this investigation 
have been reported elsewhere.5 the objectives of the pre-
sent study are: 1) to evaluate bAcH using an interuser 
assessment; 2) to refine these variables according to this 
assessment; and 3) to adapt bAcH in view of the out-
comes of these assessments. based on these, version 3 of 
the bAcH classification system will be presented.
Materials and Methods
the process of modification and optimization of the 
bAcH classification system is illustrated in Figure 1. In a 
primary analysis, we measured the applicability of the 
classification system. In a secondary analysis, we assessed 
the performance of criteria that demonstrated subopti-
mal performance in the primary analysis.
Primary interuser analysis. In all, 20 cases of osteo-
myelitis were defined. Histories of included cases 
derived from patients who attended one of two 
specialist bone infection centres within the united 
Kingdom (bone Infection unit, oxford university 
Hospitals, oxford, united Kingdom and Addenbrooke’s 
Hospital, cambridge, united Kingdom). All cases had the 
diagnosis of osteomyelitis confirmed using a validated 
composite protocol, as described elsewhere.6,7 cases 
received surgical treatment from october 2016 to April 
2017. Anonymized details of the infection were extracted 
from the patient’s medical notes and entered onto a 
secure online form. Information presented to the asses-
sors included: the osteomyelitis history (aetiology, site 
of infection, radiology imaging); microbiology (isolates 
with susceptibility testing); photographs of the soft tis-
sues overlying the site of infection; and patient comor-
bidity. radiology images were presented as single slices 
of MrI, ct, positive emission tomography (Pet)-ct, or 
radiographs (anteroposterior and lateral) chosen to best 
illustrate the condition. users were allowed as much time 
as required to complete the assessment.
A total of 30 users were recruited to complete the clas-
sification of the 20 cases. this number of users allowed 
inclusion of a wide range osteomyelitis experience, clini-
cal specialty, and centre. owing to this variation in the 
user background, this assessment contains comparably 
more users than reported in previous studies.8 users were 
required to be practising as a trauma and orthopaedic 
surgeon, plastic surgeon, or physician (infectious dis-
eases, microbiologist, or anaesthetist) and to have com-
pleted either membership or fellowship examination in 
their speciality. users were invited from a range of hospi-
tals throughout the united Kingdom, europe, and North 
America. users were given an ‘interuser key’ that 
explained how to apply the classification system without 
assistance.
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results were presented using a Fleiss’ kappa (Fκ) and 
interpreted according to landis and Koch.9 the percent-
age classification accuracy was calculated by comparing 
the user answer with the reference answer, defined by 
the authors. linear regression was performed to ascertain 
whether there was significant association between user 
attributes and the overall accuracy of classification.
Secondary interuser analysis. bone involvement: the 3D 
bone involvement analysis was performed to establish 
whether there was a limitation with using single images 
to classify the bone involvement (giving a single slice of 
a 2D image impression only) and whether this could be 
improved by using a 3D image viewer (PAcS, Insignia 
Medical Systems, basingstoke, united Kingdom) as in real 
clinical practice (thus allowing a 3D impression of the 
complete bone involvement). the secondary interuser 
assessment was performed with a selection of nine users 
who had completed the primary interuser assessment. All 
nine users were based in one centre owing to access to 
the 3D clinical imaging system being required. ten cases 
that were not included in the primary interuser assess-
ment were selected at random from a pool of cases based 
on their bone involvement score. All included cases had 
undergone surgical treatment at the bone Infection unit, 
oxford university Hospitals, oxford, united Kingdom 
between 2013 and 2017. results were presented using 
the Fκ and the percentage accuracy. to ensure that the 
sample population was representative of the total popu-
lation, the Kolmogrov–Smirnov test was performed. A 
one-way analysis of variance (ANovA) was performed to 
assess the difference between the groups.
Antimicrobial options: microbiology analysis: All cases 
of long bone osteomyelitis that received surgery in the 
bone Infection unit, oxford university Hospitals, oxford, 
united Kingdom between 2013 and 2017 were included 
for analysis (n = 253). For validation purposes, a second 
cohort from the same centre who received debridement 
surgery between 2001 and 2004 (n = 176) were used. 
the total number of sensitive and resistant susceptibility 
tests were recorded for each isolate. For the later 2013 to 
2017 cohort, all eScMID classifiable isolates were classi-
fied into MDr or non-MDr based on the eScMID crite-
ria.4 receiver operating characteristic (roc) curves were 
constructed for the number of resistant susceptibility 
tests and the percentage of susceptibility test results that 
were sensitive. For these measures, a Youden index was 
calculated10 and the optimum threshold for defining 
MDr was therefore defined. this threshold was then vali-
dated in an earlier cohort from 2001 to 2004 using the 
same methods as above.
the coverage of soft tissue and host status: the cover-
age of the soft tissues and host status variables functioned 
well in the primary analysis and therefore secondary anal-
ysis was not performed.
Results
Bone involvement. the interuser assessment of the bone 
involvement variable demonstrated accuracy of 77.0% 
(95% cI 71.5 to 82.5) among users. It had a ‘fair agree-
ment’ among users with an Fκ of 0.479 (95% cI 0.475 
to 0.483). the returned answer correlated with the refer-
ence answer in 72.3% of b1 cases, 95.0% of b2 cases, and 
82.0% of b3 cases. closer review of the cases that scored 
in the lowest quartile for accuracy demonstrated that the 
2D nature of the online form used for the data collection 
Primary interuser assessment
Secondary assessment:
- Bone involvement
- Microbiology assessment
Retrospective assessmentBACH version 1
BACH version 2
BACH version 3
Fig. 1
Flowchart presenting the development of the bAcH classification of osteo-
myelitis. Here, the development of bAcH version 2 to bAcH version 3 is 
presented. the results of the retrospective assessment have been published 
previously.5
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Fig. 2
chart showing the results of the classification of the bone involvement vari-
able using a 3D web-based picture archiving and communication system 
(webPAcS) system, as performed in clinical practice, versus using a screen-
shot of the images alone (2D group). the sample population demonstrated 
a significant improvement when completing the 3D analysis compared with 
both the total interuser population who completed the 2D analysis (95.7% 
(95% confidence interval (cI) 90.8 to 100.0) vs 77.0% (95% cI 71.2 to 82.8); 
p = 0.009, analysis of variance with Dunnett’s post hoc test and the sample 
population when completing the 2D analysis (79.3% (95% cI 62.3 to 96.3); 
p = 0.028, Student’s t-test).
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was a key limitation in the accuracy of classification. this 
was therefore explored further in a secondary analysis. 
other explanations for lower accuracy scores were due to 
unclear radiology reports and distorted anatomy.
the accuracy of classification in the 3D bone assess-
ment using webPAcS was 95.7% (95% cI 90.8 to 100.0), 
which was significantly higher when compared with the 
users’ scores in the 2D assessment (p = 0.028, paired 
t-test) and with the total population who completed the 
2D assessment (p = 0.009, ANovA with Dunnett’s post 
hoc test) (Fig. 2). this result was substantiated by an 
improvement in the Fκ in the 3D group to 0.899 (95% cI 
0.869 to 0.929), demonstrating an almost perfect agree-
ment between users. the sample population who took 
the 3D assessment were deemed to be representative of 
the total population who took the 2D assessment 
(p = 0.981, Kolmogrov–Smirnov test).
Antimicrobial options. the accuracy of classification of 
the antimicrobial options was 84.4% (95% cI 81.3 to 
87.0) with a Fκ of 0.815 (95% cI 0.811 to 0.819). this 
indicated that there was an almost perfect agreement 
among users. Despite this, microorganisms with multiple 
resistant susceptibility tests did not return an accurate 
answer with the reference answer. the returned answer 
correlated with the reference answer in only 46.7% of the 
A2 group and 10.0% of the A3 group (Fig. 3). therefore, 
an easier method than the proposed classification was 
deemed important.
the baseline characteristics for the cohorts are shown 
in table I. For the 2013 to 2017 cohort, 72/222 (32.4%) 
cases had a culture negative osteomyelitis. there were 
247 isolates, with 181 (73.3%) being eScMID-classifiable 
and 66 (26.7%) being non-eScMID-classifiable (Fig. 4a). 
the eScMID-classifiable isolates comprised of Staphy­
lococcus aureus (94/181, 51.9%), entero bacteriaceae 
(57/181, 31.5%), Pseudomonas aeruginosa (15/181, 
8.3%), and Enterococcus spp. (15/181, 8.3%) (Fig. 4b). A 
total of 40 (22.1%) were MDr, XDr, or PDr (for 
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results for the antimicrobial options variable in the interuser assessment. a) bar chart showing the individual answers in each of the cases for the antimicrobial 
options variable, organized by the reference score. the dotted line is the mean score for the antimicrobial options category (92.2%). b) Heat map demonstrating 
the returned antimicrobial options score versus the reference antimicrobial options score.
table I. Summary of the baseline characteristics of the two cohorts included in the further analysis of the microbiology
Characteristic 2013 to 2017 cohort 2001 to 2004 cohort
Patients, n  
total 253 176
excluded 31 10
Included 222 166
Age
Mean age, yrs (sd; range) 51.3 (16.0; 17 to 88) 45.0 (16.5; 12 to 90)
Sex, n (%)  
Male 166 (74.8) 121 (72.9)
Female 56 (25.2) 45 (21.1)
Growth of microorganisms, n (%)
culture-negative osteomyelitis 72 (32.4) 47 (28.3)
culture-positive osteomyelitis 150 (67.6) 119 (71.7)
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All patients
(n = 253)
Criteria not met (n = 29)
No samples (n = 2)
No growth (n = 55)
Non-significant growth (n = 17)
ESCMID-classifiable
(n = 181)
Non-ESCMID-classifiable
(n = 66)
Met inclusion criteria
(n = 222)
Patients with positive
microbiology
(n = 150)
Number of isolates
(n = 247)
Fig. 4a
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Fig. 4 (continued)
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Fig. 4e
Summary of investigations into the development of the antimicrobial options classification. a) Flowchart of patients in the 2013 to 2017 cohort and the iso-
lates grown on microbiology culture. b) chart showing the proportion of european Society of clinical Microbiology and Infectious Diseases (eScMID) isolates 
compared between the early (2001 to 2004) and late (2013 to 2017) cohort. c) receiver operating characteristic (roc) curve of number of resistant suscepti-
bility tests for eScMID classifiable isolates in the 2013 to 2017 cohort (area under the curve 98.1% (95% confidence interval (cI) 96.6 to 99.6)). d) roc curve 
demonstrating using the percentage of sensitive susceptibility tests for the eScMID classifiable isolates in the 2013 to 2017 cohort (area under the curve 98.8% 
(95% cI 98.1 to 100.0)). e) Scatterplot of each isolate from the 2013 to 2017 cohort with percentage resistant susceptibility tests against the total number of 
susceptibility tests performed. the dotted line represents four resistant tests. crosses represent multidrug-resistant (MDr) isolates and coloured dots represent 
non-MDr isolates, according to eScMID. this substantiates the results of the roc analysis where 98.3% of MDr isolates are situated on or above the dotted 
line (four resistant tests).
simplicity, termed MDr+) according to eScMID classifica-
tion. A similar number of susceptibility tests were per-
formed for non-MDr+ and MDr+ (mean 16.7 vs 16.1).
the number of resistant susceptibility tests were 
counted for each eScMID classifiable isolate. roc curves 
were constructed using the number of resistant suscepti-
bility tests and then the percentage of sensitive suscepti-
bility test results, versus criteria positive according to 
MDr+ (Figs 4c and 4d). the area under the curve (Auc) 
was calculated for each of these roc curves. using the 
number of resistant susceptibility tests, the Auc was 
98.1% (95% cI 96.6 to 99.6); using the percentage of 
sensitive susceptibility tests, the Auc was 98.8% (95% cI 
98.1 to 100.0). the Youden index demonstrated that 
optimum cut-off was the presence of four or more resist-
ant susceptibility tests (Youden index 0.85) and less than 
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78.5% sensitive susceptibility tests (Youden index 0.96). 
using these thresholds, there was a false negative rate of 
1.1% (2/181) and a false positive rate of 7.2% (13/181) in 
this cohort (table II). this suggests that the presence of 
resistance to four or more antibiotic susceptibility tests or 
a total of less than 80% susceptibility tests sensitive is a 
good measure of multidrug resistance, as defined by the 
eScMID criteria (Fig 4e).
to validate this method of classifying multidrug- 
resistant isolates, a similar analysis was performed using 
an earlier cohort of patients who received surgery in the 
same centre between 2001 and 2004 (n = 176). this 
cohort was comparable in terms of baseline characteris-
tics to the 2013 to 2017 cohort (table I). Here, the num-
ber of resistant susceptibility tests gave an Auc of 91.0% 
(95% cI 85.2 to 96.8) with an optimum threshold of four 
or more. the percentage of sensitive susceptibility tests 
gave an Auc of 91.2% (95% cI 85.4 to 96.9) with an 
optimum threshold of less than 75.8%.
Coverage of the soft tissues. In the interuser analysis, the 
coverage of the soft-tissue variable gave an accuracy of 
92.5% (95% cI 88.5 to 95.6) with a Fκ of 0.729 (95% 
cI 0.723 to 0.734). linear regression demonstrated that 
clinicians who practised within the united Kingdom 
were more likely to perform better on the coverage 
of the soft-tissue variable (94.6% vs 85.7%; p = 0.03). 
However, all plastic surgeons (n = 3) included practised 
in the united Kingdom and scored a mean of 98.3% 
on the coverage of the soft tissue variable, which could 
explain this discrepancy. the three cases that were clas-
sified the least accurately were those that included a 
small (2 cm to 3 cm) lesion on the anterior tibia. In all 
of these cases, a soft-tissue procedure was required by 
a plastic surgeon.
Host status. the host status gave an accuracy of 91.2% 
(95% cI 89.0 to 93.3) and a Fκ of 0.719 (95% cI 0.714 to 
0.725) indicating a substantial agreement among users. 
comorbidities that were consistently scored (> 95.0% of 
the time) as H2 included immune disease (e.g. autoim-
mune neutropenia), chronic kidney disease, and vascular 
pathology (e.g. stroke). Despite this, comorbidity such as 
diabetes mellitus or smoking were scored as H2 between 
50% and 75% of the time.
Discussion
the present study has demonstrated that the bAcH clas-
sification system is able to be accurately applied to adults 
with long bone osteomyelitis by users who have a variety 
of backgrounds and little previous experience of the sys-
tem. It has identified the need for optimization of the anti-
microbial options variable that allows stratification of 
resistant isolates by non-specialists.
the definition of the bone involvement variable has 
remained consistent since the first version of bAcH. the 
investigations performed as part of this study demon-
strate the importance of using software that can give a 
3D representation of the bone involvement, which 
improves the agreement and accuracy of the classifica-
tion. Despite this improvement, the combination of clini-
cal information and imaging must be used to make the 
classification. by stratifying patients into those who have 
a nonunion (segmental involvement) or adjacent joint 
involvement early in the disease process, specialist recon-
structive options may be offered at an early stage in man-
agement. this is supported by previous work that has 
demonstrated the difficulty in the management of 
infected nonunion, even in specialist centres.11,12
the initial antimicrobial options variable was based 
upon the eScMID criteria for the definitions of MDr, XDr, 
and PDr.4 the classification of the multidrug-resistant 
isolates were classified with a disappointing accuracy of 
46.7% for the A2 group (MDr isolates) and 10.0% in the 
A3 group (XDr and PDr isolates). Despite these criteria 
being detailed, they are not comprehensive and account 
for only a few species (i.e. enterobacteriaceae, Entero­
coccus spp., Pseudomonas aeruginosa, Acinetobacter spp., 
and Staphylococcus aureus). In an attempt to ensure that 
all isolates were classifiable, the version of the classifica-
tion system used in the interuser assessment included a 
line that stated that the A2 group should include “bacte-
ria that are not part of the eScMID criteria with resistance 
to appropriate antimicrobial agent”. early identification 
of multidrug-resistant isolates is essential, as delay in 
appropriate treatment is thought to be the main cause for 
mortality, rather than the virulence of the bacteria per 
se.13,14 therefore, an alternative and simple method for 
the identification of these isolates by a non-specialist is 
important, especially in cases where access to a specialist 
infectious diseases physician is not available. using the 
number of resistant or sensitive susceptibility tests means 
that the classification is easily applicable by a non- 
specialist. the limitation to this method is the variation 
between laboratories for the susceptibility testing that is 
performed for each isolate. However, guidelines for sus-
ceptibility testing, such as the european committee on 
Antimicrobial Susceptibility (eucASt) guidelines15 and 
british Society of Antimicrobial chemotherapy recom-
mendations, are increasingly being applied.16 this 
ensures that relevant and appropriate susceptibilities are 
being tested as part of a standardized operating 
table II. Summary of the classification of isolates in the 2013 to 2017 cohort 
when using the thresholds determined in the further assessment of microbi-
ology. Isolates are classified as either european Society of Microbiology and 
Infectious Diseases (eScMID) multidrug-resistant (MDr+; reference test) or 
eScMID non-MDr+ and this is compared with using either four or more resist-
ant susceptibility tests or less than 80% susceptibility tests sensitive as a meas-
ure of an isolate having either high resistance or low resistance
Resistance Reference test
 eSCMID non-MDR+ eSCMID MDR+
low resistance 128 (true negative) 2 (false negative)
High resistance 13 (false positive) 38 (true positive)
466 A. J. HotcHeN, M. DuDArevA,J. Y. FerguSoN, P. SeNDI, M. A. McNAllY    
BONE & JOINT RESEARCH
procedure.17 In any case, there is evidence to suggest the 
importance of inclusion of a specialist infectious disease 
physician or clinical microbiologist in the care of bone 
and joint infection.18
the coverage of the soft tissues is based on the require-
ment on whether a wound can be closed directly or 
whether specialist soft-tissue coverage is required. the 
accuracy of this variable was 92.5% in the interuser 
assessment. this variable does not offer advice on when 
specialist expertise is required. However, this system may 
be beneficial because it can account for the individual 
expertise of the surgeon or treating department. the 
benefit of including a plastic surgeon for limb reconstruc-
tion has been reported in the setting of lower limb 
trauma19 and also applies to bone infection.18,20
the host status can be complex to classify with mul-
tiple scoring systems available for general use21,22 and 
for use specifically in bone and joint infection.23-25 the 
distinction between defining how well controlled a 
comorbidity is and the severity of disease is important in 
outlining the prognosis to patients. Host status in osteo-
myelitis can fall into a number of categories: patients 
without health compromise who wish to have definitive 
treatment; patients with reversible or irreversible health 
compromise who wish to have treatment; and patients 
who decline treatment or who are unfit for definitive 
treatment. these groups all have differing prognosis. 
Depending on the progression of their comorbidity, age, 
and consent for surgery, they may then progress to either 
H1, H2, or H3 at a future timepoint.
the principle aim of bAcH is to guide the need for 
complex elements of management in long bone osteo-
myelitis. version 3 of bAcH is shown in Figure 5, with the 
user key presented as Supplementary Material. each vari-
able is able to determine the complexity of management 
and requirement for multidisciplinary input. the overall 
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involvement (including cortical,
medullary and non-segmental
cortico-medullary)
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B2
B3
Ax C1
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H2
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Unknown / culture negative
osteomyelitis
Bone involvement Antimicrobial options Coverage by soft tissue Host status
All isolates:
• Sensitive to ≥ 80% of
 susceptibility tests and resistant
 to ≤ 3 susceptibility tests
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• Sensitive to 0 or 1
 susceptibility test performed
Segmental infection without
joint involvement
Any bone infection with
associated joint involvement
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• Sensitive to < 80% of all
 susceptibility tests performed
  or
• Resistant to ≥ 4 susceptibility
 tests
  or
• Resistant to antibiofilm
 antibiotics in the presence of
 an implant
Direct closure possible:
Plastic surgery expertise
not required
Direct closure not possible:
Plastic surgery expertise
required
Patient with poorly controlled
comorbidity
 or
Severe comorbidity (with
evidence of end-organ damage)
 or
Recurrent osteomyelitis after
previous debridement
Unfit for definitive surgery
despite specialist intervention
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Patient declines surgery
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Fig. 5
the bAcH classification system for long bone osteomyelitis. the four key variables are headers with the corresponding criteria for making the classification in 
each. the green band denotes ‘uncomplicated’ osteomyelitis that can be managed at a non-specialist centre, the amber band denotes ‘complex’ osteomyelitis 
that should be managed at a centre with specialist expertise, and the red band is ‘limited options available’. the overall complexity of the osteomyelitis is deter-
mined by the band of the most severely classified variable.
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complexity is governed by the outcome of the most 
severely classified variable. ‘uncomplicated’ osteomyeli-
tis may be managed at a non-specialist centre, but either 
‘complex’ or ‘limited options available’ osteomyelitis 
should be referred early to a centre with appropriate 
expertise. In addition, bAcH may also be able to offer 
prognosis to patients in terms of patient-reported out-
comes, surgical complications, and medical complica-
tions. However, this has not been assessed by this study. 
In view of this, a prospective evaluation is planned to 
assess the classification system for both prognosis and 
management of bone and joint infection, with potential 
further refinement in the future.
there were limitations to this study. First, we wanted 
to ensure that the user key was read in its entirety prior to 
classification of the cases. In view of this, the password to 
gain access to the online form was placed at the foot of 
the user key document. Although this ensured that the 
document was opened, it did not ensure that it would be 
studied thoroughly. this is a pragmatic approach to 
using the classification system, which may reflect uptake 
in real clinical practice. to ensure that users understood 
the classification system, users could have been asked to 
complete a number of practice cases with feedback on 
performance prior to the full assessment. Second, cases 
included in the primary interuser assessment were 
selected to represent the frequency of clinical cases from 
the retrospective cohort.5 this resulted in an unequal 
representation of each variable (for example, there were 
13 cases of b1, two cases of b2, and five cases of b3) but 
allows the resultant accuracy and Fκ scores to indicate 
the application of bAcH in real clinical practice. third, the 
alternative method for classification of MDr isolates by 
non-specialist clinicians was not reassessed using a sec-
ond interuser assessment. We hypothesize that counting 
both the total number of performed susceptibility tests 
and number of sensitive/resistant test results would be 
easily applicable by clinicians. In addition, the method 
depends on relevant and appropriate susceptibility test-
ing of a meaningful number of antibiotics. However, this 
will be re-evaluated for accuracy and agreement between 
users in the future. Finally, the improvement observed in 
the secondary interuser assessment of the bone involve-
ment variable could be attributable the classification of 
only one variable and the inclusion of fewer cases. In the 
primary assessment, a total of 80 classifications were 
required by each user (20 cases each with four variables), 
which compares with ten classifications (ten cases with 
only one variable) in the secondary assessment. the 
higher demand in the number of classifications for the 
primary assessment could have been overbearing for cli-
nicians not experienced with the classification system, 
resulting in lower scores.
In summary, bAcH is a new classification for bone and 
joint infection. this study has optimized the variables that 
are included and has demonstrated the applicability of 
the classification system by an interuser assessment. the 
results of this study lead the way for the completion of a 
prospective assessment of bAcH in cases of long bone 
osteomyelitis to assess the management and prognosis 
of this complex condition.
Supplementary Material
the bAcH classification user key.
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